Last updated: May 26, 2026
Suppliers for Lupron Depot-Ped Kit (leuprolide acetate)
Executive summary: Lupron Depot-Ped Kit is supplied by AbbVie (producer of the branded product). Distribution into the US market is through AbbVie affiliate/authorized wholesalers; manufacturing is carried out by AbbVie’s controlled supply chain for the sterile injectable depot kit. No substitute “API supplier list” is published in a single definitive public source that maps active ingredient and kit components to named upstream manufacturers.
Who supplies Lupron Depot-Ped Kit in the US?
Answer (primary manufacturer/supplier): AbbVie supplies Lupron Depot-Ped Kit in the US market.
How to operationalize “supplier” for procurement
Procurement teams typically map to three layers:
- Marketing authorization holder / branded product manufacturer (the party responsible for FDA compliance of the marketed product).
- Wholesaler/distributor network (the entities that sell into pharmacies/hospitals).
- Direct manufacturing sites for the sterile injectable depot kit (may include multiple facilities for drug product and kit component handling).
For Lupron Depot-Ped Kit, the FDA-facing supplier identity is tied to AbbVie’s branded product control, not to a publicly disclosed “API supplier roster.”
What companies distribute Lupron Depot-Ped Kit to hospitals and pharmacies?
Answer: Authorized pharmaceutical distribution is performed through US pharmaceutical wholesalers and distributors operating under AbbVie’s distribution arrangements.
Common distributor archetypes for US oncology/pediatric injectables include national wholesalers (e.g., McKesson, Cardinal Health, AmerisourceBergen) and specialty channels, but a public, single-source mapping from AbbVie’s distribution to specific contracted distributors for Lupron Depot-Ped Kit is not provided in a way that can be stated definitively for this product.
What is the supply chain for the Lupron Depot-Ped Kit (kit components)?
Answer: The kit is a sterile injectable depot formulation delivered as a kit, meaning it includes:
- A depot-forming drug product component (leuprolide acetate formulation in depot-ready form), and
- A kit component used for reconstitution/administration (typically sterile diluent and related administration items, depending on the labeled kit configuration).
Practical implications for supplier risk
- Sterile manufacturing is the primary supply bottleneck class for depot injectables.
- Kit format means upstream shortages can come from either the drug product bulk/filled component or sterile kit components used at point-of-use reconstitution.
What FDA-listed manufacturing information identifies Lupron Depot-Ped Kit suppliers?
Answer: FDA-regulated manufacturing and label control are tied to the FDA application holder and the labeler/manufacturer identity for the finished dosage form.
What this typically resolves in practice
- The company that appears as the labeler / responsible party for the finished product
- The existence of registered manufacturing facilities used for sterile drug product manufacture
For depot injectables, the finished product typically maps to:
- AbbVie-controlled finished sterile manufacturing
- Packaging and kit fulfillment activities that may be performed across internal facilities
Is there a publicly available list of leuprolide acetate API suppliers for Lupron Depot-Ped Kit?
Answer: A complete, public, product-specific API supplier list is not available in a definitive, traceable form for Lupron Depot-Ped Kit.
How firms handle this in due diligence
Companies usually validate upstream sourcing through:
- Supplier qualification documentation
- Confidential manufacturing and control information
- Regulatory inspection history at registered facilities
- RA audits and chain-of-custody documentation
Because the question is product-specific, generic API supplier lists (for leuprolide acetate) are not a substitute for a Lupron Depot-Ped Kit-specific mapping.
What manufacturing capacity risks apply to depot injectables like Lupron Depot-Ped?
Answer: The supply risk profile is concentrated in:
- Sterile depot drug product manufacture (complex particle/depot critical quality attributes)
- Aseptic/sterile filling or aseptic handling steps
- Kit packaging and component availability (sterile diluent, reconstitution hardware)
Procurement control points
- Confirm lead times for both the finished depot kit and any critical kit components.
- Require batch traceability fields for sterile and kit components.
- Validate that the supplier network supports cold-chain or controlled room temperature requirements matching label directions (if applicable to the specific presentation and storage conditions).
How does Lupron Depot-Ped supply compare with other Lupron depot products?
Answer: The depot family is supplied under the same branded manufacturing framework by AbbVie, but presentation-specific configurations can create separate packaging and kit component dependencies.
Implication
Even if the same corporate supplier is responsible for the drug product family, supply disruptions can be presentation-specific because the kit format and kit component supply can differ across:
- Pediatric dosing presentations
- Monthly vs multi-month depot schedules
Key Takeaways
- AbbVie is the primary branded supplier for Lupron Depot-Ped Kit in the US.
- Distribution into hospitals and pharmacies uses authorized pharmaceutical wholesalers and specialty distribution channels, but a product-specific public distributor roster is not stated in a single definitive source.
- A complete, product-specific API supplier list for leuprolide acetate is not publicly available in a way that can be mapped conclusively to Lupron Depot-Ped Kit.
- Depot kit supply risk centers on sterile manufacturing and kit component availability, not only on API availability.
FAQs
1) Who is the labeler or manufacturer for Lupron Depot-Ped Kit?
The branded product is supplied by AbbVie as the manufacturer/labeler controlling the FDA-marketed product.
2) Can I source Lupron Depot-Ped Kit directly from the API manufacturer?
In practice, procurement is typically fulfilled through branded finished-product channels, not direct API sourcing, and a product-linked API supplier map is not publicly provided.
3) Are the suppliers for Lupron Depot-Ped the same as for other Lupron depot strengths?
The same brand owner (AbbVie) supplies the depot family, but kit configurations and presentation-specific components can drive different supply dependencies.
4) What parts of the Lupron Depot-Ped Kit are most likely to face supply disruptions?
The highest-risk classes are sterile depot drug product manufacturing and kit component fulfillment used for reconstitution/administration.
5) Where can a buyer verify supplier/manufacturing responsibility for Lupron Depot-Ped?
The buyer typically relies on FDA labeling/registration information for the finished product and responsible party rather than a public API supplier list.
References (APA)
- U.S. Food and Drug Administration. (n.d.). Drug product labeling and approval information for Lupron Depot-Ped Kit. FDA. https://www.fda.gov/
- DailyMed. (n.d.). Lupron Depot-Ped Kit (leuprolide acetate) label information. National Library of Medicine. https://dailymed.nlm.nih.gov/
